Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (221-230 of 269) with videos related to

Pageof 27
Sort By:
Lancet (London, England)|March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology|November 21, 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trialGeert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Crohn'S & Colitis|September 12, 2018
Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative ColitisJasper L A Vleugels, Mathew D Rutter, Krish Ragunath, et al.
Eclinicalmedicine|November 10, 2025
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel diseaseVirginia Solitano, Jurij Hanžel, Christopher Ma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR TrialSilvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's diseaseGregor Novak, Toer Stevens, Tanja Van Viegen, et al.
The Lancet. Gastroenterology & Hepatology|July 24, 2025
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trialSilvio Danese, Jessica R Allegretti, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
Pageof 27

Showing results (221-230 of 269) with videos related to

Sort By:
Pageof 27
Lancet (London, England)|March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology|November 21, 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trialGeert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Crohn'S & Colitis|September 12, 2018
Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative ColitisJasper L A Vleugels, Mathew D Rutter, Krish Ragunath, et al.
Eclinicalmedicine|November 10, 2025
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel diseaseVirginia Solitano, Jurij Hanžel, Christopher Ma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2026
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR TrialSilvio Danese, Martina Goetsch, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's diseaseGregor Novak, Toer Stevens, Tanja Van Viegen, et al.
The Lancet. Gastroenterology & Hepatology|July 24, 2025
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trialSilvio Danese, Jessica R Allegretti, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
Pageof 27